Targeted nanomedicines have revolutionised therapeutic strategies, offering new approaches for diagnosing and treating diseases, however their application in nanomedicine is often limited due to complexities associated with protein conjugations to synthetic nanocarriers. Current strategies for attaching targeting ligands to nanomaterials are complex and often inefficient and ligand density can be difficult to control. My research focuses on the design, engineering and analysis of biologicals such as antibodies for the development of novel hybrid bio-nanomaterials for application in diagnostics, imaging and drug delivery. I am particularly interested in the development of a facile method to generate actively targeted nanomaterials using polyethylene glycol (PEG)-functional nanostructures coupled to a bispecific antibody (BsAb) that exhibits dual specificity for methoxy PEG (mPEG) epitopes and cancer targets such as Epidermal Growth Factor Receptor (EGFR). Current projects include:
- Development of bispecific antibodies as tools for targeting nanomaterials to cancers for imaging and drug delivery applications.
- Development of multivalent nanomaterials using BsAb technology that can target cell surface receptors on cancers, immune cells and intracellular targets as well as delivering peptide therapeutics.
- Development of novel bio-conjugation methods to couple with BsAb technology for additional attachment of antibody fragments and other proteins to polymers.
- Identification of antibody fragments that specifically bind to different hydrophiles.